{"id":2985,"date":"2019-07-18T19:13:13","date_gmt":"2019-07-18T23:13:13","guid":{"rendered":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/exploitation-of-a-new-pharmacological-target-for-the-development-and-validation-of-new-anti-inflammatory-drugs\/"},"modified":"2024-09-03T08:59:16","modified_gmt":"2024-09-03T12:59:16","slug":"exploitation-of-a-new-pharmacological-target-for-the-development-and-validation-of-new-anti-inflammatory-drugs","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/exploitation-of-a-new-pharmacological-target-for-the-development-and-validation-of-new-anti-inflammatory-drugs\/","title":{"rendered":"Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs"},"content":{"rendered":"\n
\n\n\n\n
\n
\n

Principal Investigator:<\/strong><\/p>\n\n\n\n

Philippe Gros<\/strong>
McGill University<\/p>\n<\/div>\n\n\n\n

\n

Co-investigators<\/strong><\/p>\n\n\n\n

V\u00e9ronique Bougie<\/strong>
Corbin Therapeutics<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Completed\u00a0<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong>Project<\/strong><\/strong><\/strong><\/strong><\/strong> of $1,375,000 over 2 years<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n
    \n
  • Supported by CQDM through:<\/strong><\/strong> MEI<\/li>\n\n\n\n
  • And by a co-funding partner:<\/strong><\/strong>\n
      \n
    • Corbin Therapeutics<\/li>\n\n\n\n
    • Healthy Brains, Healthy Lives (HBHL)<\/li>\n\n\n\n
    • Brain Canada<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
      \n\n\n\n

      Challenge<\/h2>\n\n\n\n

      Neuroinflammation (NI) is involved in a diverse array of degenerative conditions, ranging from multiple sclerosis (MS) to Parkinson\u2019s and Alzheimer\u2019s disease. Although treatment options are available for MS their effectiveness is not uniform and long-term use has significant side effects. NI-based disorders remain an area of high unmet medical need and new approaches and targets are required to find disease-modifying therapies for patients.<\/p>\n\n\n\n

      Solution<\/strong><\/h2>\n\n\n\n

      In\u00a0previous studies, the team\u00a0had\u00a0discovered that inactivation of the\u00a0ubiquitin-specific protease\u00a0USP15 protects mice against lethal NI in microbial and autoimmune\u00a0experimental models.\u00a0The\u00a0current\u00a0project\u00a0successfully\u00a0developed\u00a0and validated\u00a0specific inhibitors of USP15 in view of managing and treating\u00a0NI.\u00a0More specifically, USP15 inhibitors of therapeutic value\u00a0were\u00a0developed\u00a0and optimized\u00a0in\u00a0potency, selectivity and efficacy\u00a0in blunting NI\u00a0in vitro\u00a0and\u00a0in vivo\u00a0in new animal models\u00a0that were developed as part of the project. Furthermore, the function of USP15\u00a0was\u00a0investigated in different immune cell populations and brain cells and cell-specific biochemical pathways\u00a0were\u00a0identified.\u00a0Finally,\u00a0a\u00a0mouse\u00a0model of\u00a0PD was developed and can now be\u00a0used to map out therapeutic applications of USP15 modulators.<\/p>\n\n\n\n

      Achievements\/Impac<\/strong>t<\/h2>\n\n\n\n

      Thanks\u00a0to its three funding partners,\u00a0Corbin Therapeutics,\u00a0HBHL and Brain Canada, the project\u00a0was a\u00a0success\u00a0on all\u00a0fronts. It\u00a0managed\u00a0to gain\u00a0fundamental knowledge\u00a0on the functional role of USP15 in NI,\u00a0including the\u00a0development and validation of USP15-deficient animal models\u00a0that can benefit the NI research community;\u00a0to achieve\u00a0identification of\u00a0promising therapeutics in the form of\u00a0small molecule USP15 inhibitors\u00a0tested\u00a0in vitro\u00a0and\u00a0in vivo, which will be further optimized and validated in preclinical studies; and\u00a0to\u00a0develop and validate\u00a0a Parkinson\u2019s disease mouse model.\u00a0All these activities were\u00a0quality-focused and\u00a0well\u00a0coordinated\u00a0in partnership with state-of-the-art laboratories, which positions\u00a0the\u00a0drug candidates\u00a0in a very favorable stage for clinical development by\u00a0Corbin Therapeutics.<\/p>\n","protected":false},"featured_media":3823,"template":"","project-category":[97],"class_list":["post-2985","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-biological-and-therapeutic"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/2985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3823"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2985"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=2985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}